Power Up Your Morning with iBIO NewsBrief!
Get the daily email that keeps you informed and connected in the life sciences industry
Â
📲 READ THE LATEST NEWSLETTER
iBIO IN THE NEWS
Chicago’s Biotech Boom: City Advances in GEN’s Annual Biopharma Rankings
Endotronix being acquired by California life sciences company – Crain’s Chicago
iBIO President & CEO Rings NYSE Closing Bell with CSBA Leadership
New Report Explores Latest Best Practices in State Bioscience Economic Development Initiatives
PRESS RELEASES AND BLOGS
iBIO’s EPIC Pilot Project Wraps Up, Showcasing Schools and Employers Driving Real-World Learning
iBIO Joins Urgent Call for Rare Pediatric Disease Program Reauthorization
Laughing in the Face of Pain: Amy and Pat Tomasulo’s Fight Against Trigeminal Neuralgia
Investing in Tomorrow: How 2024 Is Reshaping Biopharma’s Trajectory
MEMBER NEWS
Breakthrough in Parkinson’s Treatment: Vanqua Bio’s VQ-101 Shows Promising Results
Astellas Invests in Future of Frontotemporal Dementia Treatment with AviadoBio Partnership
Eli Lilly Boosts Indiana’s Biotech Hub with $4.5 Billion ‘Medicine Foundry’ Investment
Breakthrough in Primary Biliary Cholangitis Treatment: COUR Pharmaceuticals Reports Positive Phase 2a Results
ALL NEWS
Breakthrough in Parkinson’s Treatment: Vanqua Bio’s VQ-101 Shows Promising Results
Vanqua Bio has announced positive interim results from its Phase 1 clinical trial of VQ-101, a...
Astellas Invests in Future of Frontotemporal Dementia Treatment with AviadoBio Partnership
Astellas Pharma Inc. and AviadoBio Ltd. have announced an exclusive option and license agreement...
Eli Lilly Boosts Indiana’s Biotech Hub with $4.5 Billion ‘Medicine Foundry’ Investment
Eli Lilly and Company, a leading pharmaceutical giant, has announced plans to invest $4.5 billion...
Medicare Drug “Negotiations” 2.0: Key Changes You Need to Know
The Centers for Medicare & Medicaid Services (CMS) has announced significant changes to its...
Breakthrough in Primary Biliary Cholangitis Treatment: COUR Pharmaceuticals Reports Positive Phase 2a Results
In a significant development for patients with Primary Biliary Cholangitis (PBC), COUR...